A recent study indicated that serum ASGR2 levels could serve as a biomarker for assessing the therapeutic effects of balloon pulmonary angioplasty (BPA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). This evidence concerns the gene ASGR2 and chronic thromboembolic pulmonary hypertension.